Recent advances in chemoprevention of cancer.

Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Recent advances in our understanding of the mechanisms of carcinogenesis have led to the synthesis of new drugs that can inhibit tumor development in experimental animals by selective action on specific molecular targets, such as the estrogen, androgen, and retinoid receptors or inducible cyclooxygenase. Several of these agents (including tamoxifen, 13-cis-retinoic acid, retinyl palmitate, and an acyclic retinoid) are clinically effective in preventing the development of cancer, particularly in patients who are at high risk for developing second primary tumors after surgical removal of the initial tumor.

[1]  D. Bostwick,et al.  Androgen deprivation as a strategy for prostate cancer chemoprevention. , 1997, Journal of the National Cancer Institute.

[2]  M Buyse,et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Sporn,et al.  Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.

[4]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[5]  R. Lotan,et al.  Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. , 1997, Journal of the National Cancer Institute.

[6]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[7]  M. Sporn,et al.  Carcinogenesis and cancer: different perspectives on the same disease. , 1991, Cancer research.

[8]  M. Anver,et al.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. , 1995, Cancer research.

[9]  W. Clark,et al.  The nature of cancer: morphogenesis and progressive (self)-disorganization in neoplastic development and progression. , 1995, Acta oncologica.

[10]  M. Gottardis,et al.  Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. , 1996, Cancer research.

[11]  S. Lippman,et al.  Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Jordan Tamoxifen: the herald of a new era of preventive therapeutics. , 1997, Journal of the National Cancer Institute.

[13]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[14]  P. Vielh,et al.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis. , 1991, Gastroenterology.

[15]  S. Allison,et al.  UNDERNUTRITION AND FEMORAL FRACTURE , 1983, The Lancet.

[16]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[17]  R. Lotan,et al.  Biomarkers as intermediate end points in chemoprevention trials. , 1990, Journal of the National Cancer Institute.

[18]  J S Lee,et al.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. , 1995, The New England journal of medicine.

[19]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[20]  D. Alberts,et al.  Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. , 1994, Journal of the National Cancer Institute.

[21]  M. Boehm,et al.  Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. , 1995, Journal of medicinal chemistry.

[22]  H. Moriwaki,et al.  Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. , 1996, Digestion.

[23]  M. Sporn,et al.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. , 1991, Cancer research.

[24]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[25]  M. Bertagnolli,et al.  Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.

[26]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[28]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .